000110790 001__ 110790
000110790 005__ 20230519145522.0
000110790 0247_ $$2doi$$a10.1038/s41598-021-87352-2
000110790 0248_ $$2sideral$$a127445
000110790 037__ $$aART-2021-127445
000110790 041__ $$aeng
000110790 100__ $$aIrimia P.
000110790 245__ $$aImpact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas
000110790 260__ $$c2021
000110790 5060_ $$aAccess copy available to the general public$$fUnrestricted
000110790 5203_ $$aIdentifying highly disabled patients or at high risk of psychiatric comorbidity is crucial for migraine management. The burden of migraine increases with headache frequency, but the number of headache days (HDs) per month after which disability becomes severe or the risk of anxiety and depression is higher has not been established. Here, we estimate the number of HDs per month after which migraine is associated with higher risk of anxiety and depression, severe disability and lower quality of life. We analysed 468 migraine patients (mean age 36.8 ± 10.7; 90.2% female), of whom 38.5% had = 15 HDs per month. Our results show a positive linear correlation between the number of HDs per month and the risk of anxiety (r = 0.273; p < 0.001), depression (r = 0.337; p < 0.001) and severe disability (r = 0.519; p < 0.001). The risk of anxiety is higher in patients having = 3HDs per month, and those with = 19HDs per month are at risk of depression. Moreover, patients suffering = 10HDs per month have very severe disability. Our results suggest that migraine patients with = 10HDs per month are very disabled and also that those with = 3HDs per month should be screened for anxiety.
000110790 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000110790 590__ $$a4.997$$b2021
000110790 592__ $$a1.005$$b2021
000110790 591__ $$aMULTIDISCIPLINARY SCIENCES$$b19 / 74 = 0.257$$c2021$$dQ2$$eT1
000110790 593__ $$aMultidisciplinary$$c2021$$dQ1
000110790 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000110790 700__ $$aGarrido-Cumbrera M.
000110790 700__ $$0(orcid)0000-0001-5139-6031$$aSantos-Lasaosa S.$$uUniversidad de Zaragoza
000110790 700__ $$aAguirre-Vazquez M.
000110790 700__ $$aCorrea-Fernández J.
000110790 700__ $$aColomina I.
000110790 700__ $$aPozo-Rosich P.
000110790 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000110790 773__ $$g11, 8286 (2021), 1-9$$pSci. rep. (Nat. Publ. Group)$$tScientific reports (Nature Publishing Group)$$x2045-2322
000110790 8564_ $$s987374$$uhttps://zaguan.unizar.es/record/110790/files/texto_completo.pdf$$yVersión publicada
000110790 8564_ $$s2684301$$uhttps://zaguan.unizar.es/record/110790/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000110790 909CO $$ooai:zaguan.unizar.es:110790$$particulos$$pdriver
000110790 951__ $$a2023-05-18-15:23:12
000110790 980__ $$aARTICLE